Cereno Scientific – executive interview

Cereno Scientific (STO: CRNO-B) is a clinical-stage biotech focused on developing innovative treatments for rare indications in the cardiovascular and pulmonary spaces. Its pipeline is led by CS1 and CS014, HDAC inhibitors with disease-modifying potential in pulmonary arterial hypertension and idiopathic pulmonary fibrosis, respectively. Both candidates are backed by promising clinical data and are gearing up for more advanced-stage clinical studies (Phase IIb for CS1 and Phase II for CS014) in H126. A third asset, CS585, a prostacyclin receptor agonist, is currently under preclinical evaluation for cardiovascular indications.

In this interview, we speak with Sten Sörensen, the CEO of Cereno Scientific, focusing specifically on the two lead assets as they approach key inflection points. We discuss the recent selection of a global contract research organisation for the CS1 Phase IIb trial, the encouraging four-month data from the Expanded Access Program and the plans for CS014 following the upcoming Phase I readouts. Sten also provides further insight into the latest financing, with the improved liquidity expected to support the company’s clinical plans and partnering dialogues.